Complex biomarker tests for molecularly targeted therapies lack evidentiary standards
 

Potentially useful biomarker tests for molecularly targeted therapies are not being adopted appropriately into clinical practice because of a lack of common evidentiary standards necessary for regulatory, reimbursement, and treatment decisions.

More...